Page 1

Investing for growth

Coloplast Capital Market Day 2014

Lars Rasmussen, President & CEO

Page 2

15

32

10 15 20 25 30 35 40

Dec 08 Dec 13

Coloplast Median Best 1/4

Coloplast EBIT margin versus peer group (%)

07/08 08/09 09/10 10/11 11/12 12/13

Total Shareholder Return ~35% CAGR

63

74

Ennova benchmark Coloplast

Coloplast Engagement Survey 2014

Patient View Survey 2014

• 300 patient groups from 42 countries

• Coloplast #1

In recent years we have delivered great results

Outperforming peers

Attractive shareholder return

Motivated employees

#1 among our consumers

Page 3

We have had significant launches in all areas... - Continence Care - - Ostomy Care - - Wound Care - - Urology Care -

Page 4

OC

CC

Acces-

sories

14/15

1 2

15/16

1 2

16/17

1 2

17/18

1 2

New

Mio

...and we have the most exciting pipeline ever

13/14

1 2

UC

WSC

Page 5

We have started to invest heavily in sales pressure…

+10%

2012 2013

We are increasing rep count... ...while continuing our focus on professionalization

Page 6

...with a commitment to invest one billion DKK in sales investments between 2012 and 2015

Recurring business investments

Focus investment areas

Page 7

We believe consumer relations will be key to our future success...

Consumer

focus

Page 8

H

Coloplast Distributors Consumer

Pharmacies

Bandagists

Home Health Care

General

practitioner

Hospital

DtC

CARE

...and we want to reach out to more than 1 million consumers

Page 9

How we compete…

8

9

Untapped potential in Europe

Increased momentum in Other Developed

Markets – incl. breakthrough in US

Expansion in Emerging Markets – incl.

leadership in select countries

Wound Care leadership in key Emerging

Markets + pockets of growth in mature markets

Global potential in Urology Care

5

6

7

…Where we compete

1 Develop and market the world’s best products

4 Secure an efficient setup

2 Interact and build consumers relations

3 Invest in sales pressure

Our strategy remains centred on value creation through profitable organic growth

Page 10

Beyond 2015 we see potential for further sales investments - Key areas for further investments -

Continence Care

Ostomy Care

Wound & Skin Care

Urology Care

European Markets Other Developed

Markets

Emerging Markets

Expand Wound Care

Direct-to-Consumer Capture fair share Build markets and

secure leadership

Page 11

Today, we would like to share with you our new and more ambitious long term guidance

7 – 10%

Revenue growth

- annual organic -

0.5 – 1.0%

EBIT margin

- annual expansion -

Page 12

In sum, we believe we can deliver significant organic value creation through...

…interacting and becoming even

closer to our consumer

…developing and marketing the

world’s best products

…accelerating growth

and leveraging our efficient and

scalable set-up

Page 13